Collectively, these data suggest that lefamulin disrupts GCN5/CBP‐mediated acetylation of ILF3, and subsequently inhibits the transcriptional activity of ILF3, enhancing the sensitivity of sorafenib in HCC. The gene discussed is ILF3; the disease is hepatocellular carcinoma.